Compare GAME & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GAME | SCYX |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.4M | 44.4M |
| IPO Year | 2024 | 2014 |
| Metric | GAME | SCYX |
|---|---|---|
| Price | $3.06 | $4.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | ★ 174.3K | 68.2K |
| Earning Date | 04-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.14 | 61.36 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $44,999,302.00 | $257,000.00 |
| Revenue This Year | $87.12 | N/A |
| Revenue Next Year | $21.14 | $608.78 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.24 | $0.57 |
| 52 Week High | $3.85 | $6.09 |
| Indicator | GAME | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 54.19 |
| Support Level | N/A | $4.65 |
| Resistance Level | N/A | $5.10 |
| Average True Range (ATR) | 0.00 | 0.33 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 0.00 | 67.15 |
GameSquare Holdings Inc is a vertically integrated digital media, entertainment, and technology company focused on gaming and youth culture audiences. The company operates through four reportable segments: Owned and Operated IP, Agency, SaaS and managed services, and Yield. It provides services including influencer marketing, esports talent management, creative production, merchandise and consumer products, live streaming analytics, and digital media solutions through its various brands and platforms. It generates the majority of its revenue from the Agency segment.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.